ABBV : Analysis & Opinions

  1. Top 4 Medicinal Marijuana Stocks for 2017

    January 18, 2017
    The medicinal marijuana industry could be ready to soar, and these 4 stocks are top picks.
  2. Biosimilar Drugs To Take On Top Brand Names

    January 4, 2017
    Makers of biosimilar drugs may erode the market share of top brand names as competition heats up.
  3. Momenta's Humira Biosimilar Looks Promising (MNTA)

    November 30, 2016
    Momenta' psoriasis drug did well in a recent study, and could give Abbvie's Humira some serious competition.
  4. AbbVie Ends Halozyme Enhanze Development Program (HALO, ABBV)

    November 22, 2016
    AbbVie ended a drug development partnership with Halozyme Therapeutics after a failed study.
  5. J&J’s Humira Rival Needs More Work (JNJ, ABBV)

    November 15, 2016
    J&J’s rheumatoid arthritis drug sirukumab produced mixed results in a recent study.
  6. AbbVie Crushes Humira Patent Challenge (ABBV, CHRS)

    November 8, 2016
    The U.S. Patent and Trademark Office denied Coherus BioSciences' application to invalidate AbbVie's Humira drug.
  7. AbbVie 3Q Net 97 Cents/Shr on $6.4B Revenue (ABBV)

    October 30, 2016
    AbbVie reported 3Q earnings of $1.6 billion, or 97 cents per share, on revenue of $6.4 billion.
  8. Drug Wars: California Vote Could Limit Price Hikes

    October 19, 2016
    Major drug companies have spent $60 million to defeat a referendum calling for price limits
  9. AbbVie Leukemia Drug Clears European Hurdle (ABBV)

    October 19, 2016
    AbbVie's leukemia drug Venclyxto received a positive opinion from Europe's CHMP, paving the way for its entry into the lucrative ...
  10. High Valuations Hammer Dividend Stocks (AES, EXC)

    October 10, 2016
    Investors have been fleeing dividend stocks with high valuations, but strong opportunities still exist.
  11. AbbVie Expands Operation in Singapore (ABBV)

    September 29, 2016
    AbbVie has expanded its operations in Asia with a manufacturing facility in Singapore. Doing business in Singapore could ...
  12. Amgen's Biosimilar Gets FDA Approval (AMGN, ABBV)

    September 27, 2016
    The company’s first biosimilar, Amjevita, is now approved for seven common inflammatory ailments and may encroach on AbbVie's ...
  13. Trend Channel Buying Opportunity in These Stocks (ABBV, RTN)

    September 21, 2016
    These stocks are rising within trend channels and flashing a buy signal with the price near channel support.
  14. Top 5 Drug Stocks of 2016 (ABBV, JNJ)

    August 19, 2016
    Discover analyses of the top five drug stocks, and learn why investors should consider these stocks due to the stocks' attractive ...
  15. Top 5 Pharmaceutical Stocks of 2016 (ABBV, JNJ)

    August 9, 2016
    These 5 top-performing pharmaceutical stocks have 2016 product offerings and pipeline prospects that make them a solid bet ...
  16. Biogen Trounces Q2 Estimates; CEO to Retire Soon

    July 22, 2016
    Thursday was a busy and memorable day for Biogen (NASDAQ: BIIB): The noted biopharma released its latest set of quarterly ...
  17. Stocks to Buy Along Trendline Support (ABBV, MXL)

    July 5, 2016
    These stocks are near or approaching trendline support, which is often a favorable time to buy.
  18. FDA Approves Biogen and AbbVie's MS Treatment

    May 31, 2016
    A pair of prominent pharmaceutical companies, AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB), have gotten an important regulatory ...
  19. Huawei Building Way to Live Forever: in the Matrix

    May 21, 2016
    Chinese smartphone maker Huawei envisions a future in which human beings are able to upload their consciousness into computers ...
  20. 5 Reasons Why Spinoff Companies Can Be a Buy for Investors (ABBV, ...

    May 19, 2016
    Learn how investors can profit from investing in spinoff companies, and discover two ETFs that offer exposure to a basket ...
  21. Why Biogen Is Hiving Off Its Hemophilia Business

    May 4, 2016
    Noted biotech Biogen is preparing a key divestment. The company revealed Tuesday that it will spin off its hemophilia business ...
  22. Dividend Payout vs. Dividend Growth: Which Ratio Should You Prefer? ...

    May 3, 2016
    Learn why growth investors should focus on dividend payouts, and which large-company stocks are capable of sustaining earnings ...
  23. (VRX) Who are Valeant's Main Competitors?

    April 23, 2016
    Learn which companies Valeant is likely watching closely, since it is known for acquiring companies for their products rather ...
  24. American Funds Capital Income Builder Trends in 2016 (CAIBX)

    April 15, 2016
    Learn about the composition of the American Funds Capital Income Builder fund, and discover how its makeup has evolved between ...
  25. Is there any Upside in Neurocine Biosciences, Inc? (NBIX)

    April 11, 2016
    Learn about the key drivers of Neurocrine Biosciences' stock price in the near-term. This attempts to shed light on what ...
  26. Bristol-Myers Squibb Buys Into Hot Pharma Segment

    April 4, 2016
    Bristol-Myers Squibb (NYSE: BMY) is readying itself for a fresh acquisition. The pharmaceutical giant announced last month ...
  27. Is Big Pharma Under Pressure in 2016? (JNJ, GSK)

    March 8, 2016
    Find out why large pharmaceutical companies are coming under pressure by investors to break themselves up into smaller companies.
  28. Top 5 Positions in Morgan Stanley's Portfolio (MS, SPY)

    February 27, 2016
    Learn about Morgan Stanley and the type of business it operates. Understand what makes up its portfolio as well as the top ...
  29. The Top Rated Dividend Paying Stocks for 2016 (ABBV, BA)

    February 9, 2016
    Discover five of the top-rated stocks that pay investors solid dividends that you may want to consider adding to your investment ...
  30. Is AbbVie a Good Stock To Buy?

    January 19, 2016
    A look at AbbVie Inc., one of the newly-formed companies in the pharmaceutical space.
  31. Parabolic SAR Buy Signals in Beaten Down Stocks (ABBV, CVX)

    November 2, 2015
    These four stocks recently flashed a Parabolic SAR buy signal after declining for some time. Should you be looking for more ...
  32. FDA's Warning Shakes Up Hep C Landscape

    October 23, 2015
    Yesterday, the FDA issued a warning highlighting the risk of potential serious liver injury with Viekira Pak, a drug used ...
  33. The 5 Best Dividend Stocks in the Healthcare Sector (GSK, ABBV)

    October 7, 2015
    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash ...
  34. Are Drug Price Controls Viable in the U.S.? (IPXL, ABBV)

    September 24, 2015
    Are price controls on pharmaceuticals viable in the U.S.? What effect would they have on existing drug companies and their ...
  35. 4 Ways Millennials Can Buy Private Businesses

    July 23, 2015
    Buying private businesses is a good way to have greater control over your investments while increasing your income and avoiding ...
  36. Are These 3 Biotech Stocks Dirt Cheap? (ABBV, AMAG)

    June 22, 2015
    Everyone loves a bargain, and investors like me are no exception. That's why I like to check in with stocks every quarter ...
  37. Most Important Mergers And Acquisitions Of 2015

    June 15, 2015
    Nearly halfway through the year, 2015 is proving to be a big one for mergers and acquisitions.
  38. How Does Biogen Make its Money?

    June 2, 2015
    Biogen is a healthy biotechnology company producing a stream of illness-fighting drugs. Its big sellers treat MS, and it ...
  39. The Most Important Number for Gilead Shareholders (GILD, ABBV)

    May 12, 2015
    It's been nearly two weeks since biotech blue chip stock Gilead Sciences (NASDAQ: GILD) reported its first-quarter earnings ...
  40. Gilead Earnings Preview: What You Should Know (GILD, ABBV)

    April 22, 2015
    Perhaps no biotechnology stock has shaped what it means to improve patient quality of care more in recent years than Gilead ...
  41. How Gilead Plans to Keep Competitors in Check (GILD, ABBV)

    April 14, 2015
    Gilead Sciences (NASDAQ: GILD) has plenty of experience in outmaneuvering competitors. After all, despite competitors' launching ...
  42. How is a Spinoff Worth $100 Billion? See AbbVie

    April 1, 2015
    An in depth look at Abbott Labs spinoff AbbVie and how it became a nearly $100 billion company.
  43. Read This Before You Sell Gilead Sciences (GILD, ABBV)

    March 25, 2015
    Earlier this week, Gilead Sciences (NASDAQ: GILD) reported that nine people who were taking a specific heart disease drug ...
  44. Why These Could Be 2015's 10-Best Pharma Stocks (ABBV, ALXN)

    March 17, 2015
    The pharmaceutical stocks covered here have significant potential going forward. Here's why.
  45. A Multi-Asset Income ETF For Defensive Investors

    November 14, 2014
    In light of market volatility and worries that stocks are overbought, one product worth noting is the Guggenheim Multi-Asset ...
  46. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  47. Biotechnology Stocks To Keep on the Radar

    April 23, 2014
    Health care is showing a resurgance, lead by biotechnology. Here are the opportunites to watch.
  48. Abbott Labs Spins Off AbbVie: Which Is The Better Buy?

    January 4, 2013
    January 2 was the first day of trading for the pharmaceutical spin-off.